Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Awakn Life Sciences Corp C.AWKN

Alternate Symbol(s):  AWKNF

Healthcare Psychedelics
Awakn Life Sciences Corp. is a Canada-based clinical-stage biotechnology company. The Company is developing therapeutics for substance use and mental health disorders, with a near-term focus on Alcohol Use Disorder (AUD). The Company's therapeutics are focused on the brain circuits that drive addiction, multiple receptors rather than the traditional single drug receptor targets. The Company... see more

Recent & Breaking News (CSE:AWKN)

Awakn Life Sciences Announces Credit Facility

Newsfile 4 days ago

Canadian Investment Regulatory Organization Trading Halt - AWKN

Canada NewsWire 6 days ago

Awakn Life Sciences Enters into Binding Letter of Intent for Acquisition of Awakn by Graft Polymer (UK) Plc

Newsfile 6 days ago

Awakn Announces Promising Results from Aminoindane New Chemical Entity Pre-Clinical Program

Newsfile 12 days ago

Awakn Announces Opening of Four Additional AWKN-001 Phase 3 Trial Sites

Newsfile October 22, 2024

Awakn Partners with the University of Nottingham for in Vivo Testing of Aminoindane New Chemical Entity (NCE) Pre-Clinical Program

Newsfile October 15, 2024

Awakn Selects Eurofins Discovery for Pharmacology Testing in New Chemical Entity (NCE) Pre-Clinical Program

Newsfile October 4, 2024

Awakn Life Sciences Announces Upsizing and Closing of Tranche of Private Placement Financing

Newsfile September 18, 2024

Awakn Announces Key Progress in Its Aminoindane Pre-Clinical Program

Newsfile August 28, 2024

Awakn Announces First Patient Screened in Phase 3 Clinical Trial of AWKN-001 for Severe Alcohol Use Disorder

Newsfile August 9, 2024

Awakn Life Sciences Announces Closing of Tranche of Private Placement and Warrant Extension

Newsfile July 31, 2024

Awakn Life Sciences Provides Update on Aminoindane New Chemical Entity Patent Portfolio

Newsfile July 22, 2024

Awakn Life Sciences Announces Collaboration Agreement with Graft Polymer (UK) PLC

Newsfile July 18, 2024

Awakn Life Sciences Announces Closing of Tranche of Private Placement

Newsfile June 4, 2024

CSE Bulletin: Reinstatement - Awakn Life Sciences Corp. (AWKN)

Newsfile May 31, 2024

Canadian Investment Regulatory Organization Trade Resumption - AWKN

Canada NewsWire May 31, 2024

CSE Bulletin: Suspensions - AWKN, BHCC, BZAM, GLOW, VTAL, JKPT, MEAL,VFI.X, STHZ

Newsfile May 8, 2024

Canadian Investment Regulatory Organization Trading Halt - AWKN

Canada NewsWire May 8, 2024

Awakn Life Sciences Discusses Filing of Financial Statements

Newsfile May 2, 2024

Awakn Life Sciences Announces Closing of Tranche of Private Placement

Newsfile April 17, 2024